Navigation Links
SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants

SANTA CRUZ, Calif., Nov. 12, 2012 /PRNewswire/ -- SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, has been awarded US Patent No. 8,283,460 for key aspects of the company's sshRNA therapeutic platform.  sshRNAs are small synthetic stem-loop (or hairpin) RNAs that the company's researchers have shown to be highly potent in knocking down target RNAs through an RNA interference (RNAi) mechanism.  SomaGenics' lead therapeutic program targets hepatitis C, and a number of sshRNAs directed at the hepatitis C virus are covered by the new patent.  'This patent, following on the award of US Patent 7,902,351 in 2011, represents another significant milestone in securing comprehensive patent protection for our sshRNA technology," commented SomaGenics CEO Brian Johnston.

SomaGenics also announced the receipt of two Small Business Innovation Grants from the National Institutes of Health totaling $647,000.  One, from the National Institute of General Medical Sciences, is entitled Accelerating Wound Healing Using RNAi and aims to speed healing of the hard-to-heal wounds that can particularly plague diabetics.  Dr. Sumedha Jayasena, VP of Therapeutic Development at SomaGenics, is principal investigator.

A second grant, awarded by the National Cancer Institute, is entitled A Novel Method for Quantitation of Fragmented mRNAs.  Its goal is to develop a new approach to analyzing gene expression from formalin-fixed, paraffin-embedded (FFPE) tissue specimens. Large repositories of FFPE specimens, each with pathologist interpretation and clinical records, are available at many medical institutions.  The ability to determine gene expression profiles for each specimen could make these archives a rich resource for discovering mRNA biomarkers of disease. Although RT-qPCR is the preferred method for quantitative analysis of gene expression, its sensitivity and robustness are significantly reduced with FFPE samples due to the degradation of mRNAs that occurs during specimen preparation and storage. SomaGenics' mR-FQ RT-qPCR approach should overcome these problems because, unlike standard PCR methods, it is unaffected by fragmentation; indeed, it explicitly makes use of it. The principal investigator for this grant is Dr. Sergei Kazakov, VP of Discovery Research at SomaGenics.

The new awards bring SomaGenics' total grant funding to well over $18 million and allow the company to develop new applications for its technologies.


Dr. Brian Johnston
CEO, SomaGenics, Inc.
831-426-7700 x12

This press release was issued through eReleases® Press Release Distribution. For more information, visit

SOURCE SomaGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
2. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
3. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
4. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
5. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
7. Boston Childrens Hospital announces international genomics competition winner
8. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
9. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
10. AMRI Announces Third Quarter 2012 Results
11. Egenix, Inc. Announces New Director
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: ... been advised by its major shareholders, Clean Technology Fund ... United States based venture capital funds ... of Biorem (on a fully diluted, as converted basis), ... disposition of their entire equity holdings in Biorem to ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer ... what they believe could be a new and helpful biomarker for malignant pleural ... Click here to read it now. , Biomarkers are components in the ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):